|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.58 USD | -5.66% |
|
-29.43% | +1.53% |
| 07-31 | Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial | MT |
| 07-31 | Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -5.66% | -29.43% | -31.53% | -18.65% | +1.53% | +226.23% | +136.90% | -42.36% | - | 1.4B | |
| -0.36% | +0.14% | -2.44% | +16.90% | +4.17% | -0.95% | +14.33% | -22.13% | +207.63% | 48.53B | |
| -2.49% | -2.45% | -3.44% | +24.04% | +130.33% | +393.44% | +475.29% | +521.69% | - | 39.87B | |
| -1.14% | +8.86% | +12.69% | +44.22% | +2.97% | +27.01% | +7.31% | -7.15% | +201.28% | 38.68B | |
| -1.38% | -4.66% | +0.40% | +4.57% | +2.27% | +2.11% | +50.96% | -9.00% | +1,068.52% | 35.13B | |
| -2.41% | +2.59% | +3.17% | -4.58% | +5.70% | +11.68% | +41.16% | -15.90% | +153.21% | 29.79B | |
| -0.26% | -2.65% | +1.53% | +37.58% | +2.15% | +32.67% | +122.34% | +224.80% | - | 16.11B | |
| +0.13% | -4.11% | -9.30% | +6.25% | - | - | - | - | - | 16.08B | |
| -0.62% | +1.23% | -2.34% | +17.08% | +8.56% | +1.80% | +15.05% | -33.78% | +80.78% | 13.61B | |
| -3.21% | -7.17% | -8.34% | +39.93% | -14.02% | -4.93% | -37.59% | -35.81% | +106.48% | 12.62B | |
| +0.09% | +0.71% | +1.70% | +31.76% | +22.64% | +31.42% | -10.97% | -40.05% | +156.10% | 11.23B | |
| -1.11% | +2.80% | -0.37% | +33.81% | +15.59% | +37.32% | +14.41% | -43.93% | +168.24% | 11.2B | |
| +0.94% | -5.21% | -20.52% | +7.19% | -10.88% | +75.33% | +540.98% | +270.00% | +2,491.79% | 10.54B | |
| -0.00% | -0.13% | +0.45% | +60.50% | +77.66% | +260.10% | +534.94% | - | - | 10.07B | |
| -1.98% | -6.38% | +23.91% | +23.06% | +26.87% | +19.83% | +28.50% | -60.84% | - | 9.09B | |
| -2.76% | -1.14% | +1.91% | +34.66% | +53.44% | +148.96% | +621.67% | +172.06% | - | 8.79B | |
| +3.45% | -4.97% | -36.07% | -29.52% | -32.78% | +22.39% | +34.91% | +40.65% | +40.95% | 8.6B | |
| -1.56% | -4.21% | -3.51% | -10.40% | +2.63% | +492.07% | +1,952.73% | +36.07% | - | 8.58B | |
| +1.76% | +1.96% | +6.99% | +23.34% | -11.52% | -20.81% | -19.53% | -28.51% | +35.90% | 8.56B | |
| -2.54% | -8.71% | -12.45% | +20.19% | +29.12% | +130.12% | +320.73% | +67.45% | - | 8.51B | |
| Average | -0.93% | -2.33% | -3.88% | +18.10% | +16.65% | +99.25% | +254.95% | +55.18% | +428.26% | 17.35B | |
| Weighted average by Cap. | -1.00% | +0.53% | -0.90% | +19.86% | +22.48% | +87.42% | +185.25% | +78.42% | +406.87% |
- Stock Market
- Stocks
- GLUE Stock
- Sector Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
